LONDON, February 20, 2013 /PRNewswire/ --
Small-cap biotech stocks can provide big returns when they have a blockbuster drug in their portfolio. As in the case of Incyte Corporation (NASDAQ: INCY), the stock provided steep returns while the company's fortune is dependent on just one drug. The company announced strong Q4 results and provided robust outlook for the future performance. Arena Pharmaceuticals Inc. (NASDAQ: ARNA) also made impressive move on the strength of its obesity drug, Belviq. While these companies carry higher risk profile, the returns also commensurate risks. StockCall professionals have completed their technical analysis on Incyte and Arena Pharmaceuticals; and these free reports are accessible by registering at http://www.stockcall.com/research
Incyte Bets on Baricitinib
Incyte's stock jumped after its results declaration. The company reported its fourth quarter EPS at 14 cents per share, up from 44 cents in net loss it had reported for the corresponding quarter of the last year. Its revenue also showed the equally impressive improvement and jumped from $28.9 million to $113.9 million. The stock is making good moves too as it logged 32 percent return so far in this year. Incyte now expects its full year revenue to be in the range of $210 million and $225 million. Sign up for the free technical research on Incyte Corp. at http://www.StockCall.com/INCY022013.pdf
Incyte is also big on collaborations and has inked deals with big names like Novartis, with which it has exclusive rights arrangements for its super performer drug Jakafi. The drug improved its revenue from $2 million to the current level of $43.3 million. The company also collaborates with Eli Lilly for Baricitinib. The drug is being developed as a potential treatment for RA. Thus, Incyte has one well performing drug in its portfolio and another potential blockbuster drug is in the pipeline. With good results and solid outlook, the company is expected to perform well in to the future. These catalysts also bode well for the stock price and Incyte comes across as a good investment opportunity.
Arena Pharma Waits for EU Approval
Arena is in the news for its potential fat busting drug Belviq. The drug will directly compete with Vivus developed Qsymia. While any anti-obesity drug seems to have a readymade market with obesity rate higher than before, many previous attempts have failed. Pfizer's Exubera failed to make its mark in the market. Vivus' Qsymia also logged lower-than-expected sales numbers. This makes the scenario rather bleak for Arena Pharma. Be sure to read our latest technical research on Arena Pharmaceuticals Inc. by registering at http://www.StockCall.com/ARNA022013.pdf
The company also seeks EU approval for its drug. However, the path to approval is not easy. The drug is already approved for sale in the U.S. Thus, the company is not only grappling with uncertainty regarding the drug's performance in the U.S. market, it is also skeptical about receiving EU approval. Though, the chances of getting the drug rejected by the EU authorities are minimal, but the process can take a long time.
On the plus side, Arena Pharma collaborates with Eisai for the drug's U.S. launch. The collaboration will help the company in the more effective launch and distribution of Belviq. The consensus expectations for the drug are on the milder side. Hence, any good sales performance by the drug will prove to be a major positive catalyst for the stock.
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at http://www.stockcall.com